论文部分内容阅读
目的探讨99mTc-MIBI显像预测乳腺癌新辅助化疗(NCT)疗效的临床价值。方法 50例局部进展期乳腺癌(LABC)患者化疗前行99m Tc-MIBI显像,计算早期摄取比值(EUR)、晚期摄取比值(DUR)及清除率[WR=(EURDUR)/EUR×100%]。按照WHO制定的实体瘤疗效评定标准评价疗效,对化疗有效组及化疗无效组WR、EUR、DUR进行统计学比较。结果化疗有效组与化疗无效组在WR、EUR、DUR值比较差异均有统计学意义(P<0.05)。结论99mTc-MIBI乳腺肿瘤显像中摄取与清除率WR在治疗有效组与无效组中均有统计学意义,肿瘤99mTc-MIBI摄取越高,清除率越低,疗效越好,可有效预测LABC患者术前NCT疗效。
Objective To investigate the clinical value of 99mTc-MIBI imaging in predicting the efficacy of neoadjuvant chemotherapy (NCT) in breast cancer. Methods Fifty patients with locally advanced breast cancer (LABC) underwent 99m Tc-MIBI imaging before chemotherapy. The rates of early intake (EUR), late intake (DUR) and clearance rate were calculated. ]. According to WHO evaluation criteria for the evaluation of solid tumors to evaluate the efficacy of chemotherapy and chemotherapy ineffective group WR, EUR, DUR for statistical comparison. Results There were significant differences in WR, EUR and DUR between the chemotherapy-effective group and the chemotherapy-ineffective group (P <0.05). Conclusion Uptake and clearance rate of 99mTc-MIBI in breast tumor imaging are statistically significant in the treatment-effective group and in the ineffective group. The higher 99mTc-MIBI uptake, the lower the clearance rate, the better the curative effect, which can effectively predict the patients with LABC Preoperative NCT efficacy.